IBDEI10I ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,16463,1,4,0)
;;=4^C92.01
;;^UTILITY(U,$J,358.3,16463,2)
;;=^5001790
;;^UTILITY(U,$J,358.3,16464,0)
;;=C92.00^^61^775^8
;;^UTILITY(U,$J,358.3,16464,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16464,1,3,0)
;;=3^Acute Myeloblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,16464,1,4,0)
;;=4^C92.00
;;^UTILITY(U,$J,358.3,16464,2)
;;=^5001789
;;^UTILITY(U,$J,358.3,16465,0)
;;=C92.61^^61^775^9
;;^UTILITY(U,$J,358.3,16465,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16465,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
;;^UTILITY(U,$J,358.3,16465,1,4,0)
;;=4^C92.61
;;^UTILITY(U,$J,358.3,16465,2)
;;=^5001808
;;^UTILITY(U,$J,358.3,16466,0)
;;=C92.60^^61^775^10
;;^UTILITY(U,$J,358.3,16466,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16466,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
;;^UTILITY(U,$J,358.3,16466,1,4,0)
;;=4^C92.60
;;^UTILITY(U,$J,358.3,16466,2)
;;=^5001807
;;^UTILITY(U,$J,358.3,16467,0)
;;=C92.A1^^61^775^11
;;^UTILITY(U,$J,358.3,16467,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16467,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
;;^UTILITY(U,$J,358.3,16467,1,4,0)
;;=4^C92.A1
;;^UTILITY(U,$J,358.3,16467,2)
;;=^5001814
;;^UTILITY(U,$J,358.3,16468,0)
;;=C92.A0^^61^775^12
;;^UTILITY(U,$J,358.3,16468,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16468,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
;;^UTILITY(U,$J,358.3,16468,1,4,0)
;;=4^C92.A0
;;^UTILITY(U,$J,358.3,16468,2)
;;=^5001813
;;^UTILITY(U,$J,358.3,16469,0)
;;=C92.51^^61^775^13
;;^UTILITY(U,$J,358.3,16469,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16469,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,16469,1,4,0)
;;=4^C92.51
;;^UTILITY(U,$J,358.3,16469,2)
;;=^5001805
;;^UTILITY(U,$J,358.3,16470,0)
;;=C92.50^^61^775^14
;;^UTILITY(U,$J,358.3,16470,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16470,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,16470,1,4,0)
;;=4^C92.50
;;^UTILITY(U,$J,358.3,16470,2)
;;=^5001804
;;^UTILITY(U,$J,358.3,16471,0)
;;=C94.40^^61^775^17
;;^UTILITY(U,$J,358.3,16471,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16471,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
;;^UTILITY(U,$J,358.3,16471,1,4,0)
;;=4^C94.40
;;^UTILITY(U,$J,358.3,16471,2)
;;=^5001843
;;^UTILITY(U,$J,358.3,16472,0)
;;=C94.42^^61^775^15
;;^UTILITY(U,$J,358.3,16472,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16472,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
;;^UTILITY(U,$J,358.3,16472,1,4,0)
;;=4^C94.42
;;^UTILITY(U,$J,358.3,16472,2)
;;=^5001845
;;^UTILITY(U,$J,358.3,16473,0)
;;=C94.41^^61^775^16
;;^UTILITY(U,$J,358.3,16473,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16473,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
;;^UTILITY(U,$J,358.3,16473,1,4,0)
;;=4^C94.41
;;^UTILITY(U,$J,358.3,16473,2)
;;=^5001844
;;^UTILITY(U,$J,358.3,16474,0)
;;=D62.^^61^775^18
;;^UTILITY(U,$J,358.3,16474,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16474,1,3,0)
;;=3^Acute Posthemorrhagic Anemia
;;^UTILITY(U,$J,358.3,16474,1,4,0)
;;=4^D62.
;;^UTILITY(U,$J,358.3,16474,2)
;;=^267986
;;^UTILITY(U,$J,358.3,16475,0)
;;=C92.41^^61^775^19
;;^UTILITY(U,$J,358.3,16475,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI10I 3777 printed Sep 23, 2025@19:35:21 Page 2
IBDEI10I ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,16463,1,4,0)
+2 ;;=4^C92.01
+3 ;;^UTILITY(U,$J,358.3,16463,2)
+4 ;;=^5001790
+5 ;;^UTILITY(U,$J,358.3,16464,0)
+6 ;;=C92.00^^61^775^8
+7 ;;^UTILITY(U,$J,358.3,16464,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,16464,1,3,0)
+10 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
+11 ;;^UTILITY(U,$J,358.3,16464,1,4,0)
+12 ;;=4^C92.00
+13 ;;^UTILITY(U,$J,358.3,16464,2)
+14 ;;=^5001789
+15 ;;^UTILITY(U,$J,358.3,16465,0)
+16 ;;=C92.61^^61^775^9
+17 ;;^UTILITY(U,$J,358.3,16465,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,16465,1,3,0)
+20 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
+21 ;;^UTILITY(U,$J,358.3,16465,1,4,0)
+22 ;;=4^C92.61
+23 ;;^UTILITY(U,$J,358.3,16465,2)
+24 ;;=^5001808
+25 ;;^UTILITY(U,$J,358.3,16466,0)
+26 ;;=C92.60^^61^775^10
+27 ;;^UTILITY(U,$J,358.3,16466,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,16466,1,3,0)
+30 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
+31 ;;^UTILITY(U,$J,358.3,16466,1,4,0)
+32 ;;=4^C92.60
+33 ;;^UTILITY(U,$J,358.3,16466,2)
+34 ;;=^5001807
+35 ;;^UTILITY(U,$J,358.3,16467,0)
+36 ;;=C92.A1^^61^775^11
+37 ;;^UTILITY(U,$J,358.3,16467,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,16467,1,3,0)
+40 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
+41 ;;^UTILITY(U,$J,358.3,16467,1,4,0)
+42 ;;=4^C92.A1
+43 ;;^UTILITY(U,$J,358.3,16467,2)
+44 ;;=^5001814
+45 ;;^UTILITY(U,$J,358.3,16468,0)
+46 ;;=C92.A0^^61^775^12
+47 ;;^UTILITY(U,$J,358.3,16468,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,16468,1,3,0)
+50 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
+51 ;;^UTILITY(U,$J,358.3,16468,1,4,0)
+52 ;;=4^C92.A0
+53 ;;^UTILITY(U,$J,358.3,16468,2)
+54 ;;=^5001813
+55 ;;^UTILITY(U,$J,358.3,16469,0)
+56 ;;=C92.51^^61^775^13
+57 ;;^UTILITY(U,$J,358.3,16469,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,16469,1,3,0)
+60 ;;=3^Acute Myelomonocytic Leukemia,In Remission
+61 ;;^UTILITY(U,$J,358.3,16469,1,4,0)
+62 ;;=4^C92.51
+63 ;;^UTILITY(U,$J,358.3,16469,2)
+64 ;;=^5001805
+65 ;;^UTILITY(U,$J,358.3,16470,0)
+66 ;;=C92.50^^61^775^14
+67 ;;^UTILITY(U,$J,358.3,16470,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,16470,1,3,0)
+70 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
+71 ;;^UTILITY(U,$J,358.3,16470,1,4,0)
+72 ;;=4^C92.50
+73 ;;^UTILITY(U,$J,358.3,16470,2)
+74 ;;=^5001804
+75 ;;^UTILITY(U,$J,358.3,16471,0)
+76 ;;=C94.40^^61^775^17
+77 ;;^UTILITY(U,$J,358.3,16471,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,16471,1,3,0)
+80 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
+81 ;;^UTILITY(U,$J,358.3,16471,1,4,0)
+82 ;;=4^C94.40
+83 ;;^UTILITY(U,$J,358.3,16471,2)
+84 ;;=^5001843
+85 ;;^UTILITY(U,$J,358.3,16472,0)
+86 ;;=C94.42^^61^775^15
+87 ;;^UTILITY(U,$J,358.3,16472,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,16472,1,3,0)
+90 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
+91 ;;^UTILITY(U,$J,358.3,16472,1,4,0)
+92 ;;=4^C94.42
+93 ;;^UTILITY(U,$J,358.3,16472,2)
+94 ;;=^5001845
+95 ;;^UTILITY(U,$J,358.3,16473,0)
+96 ;;=C94.41^^61^775^16
+97 ;;^UTILITY(U,$J,358.3,16473,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,16473,1,3,0)
+100 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
+101 ;;^UTILITY(U,$J,358.3,16473,1,4,0)
+102 ;;=4^C94.41
+103 ;;^UTILITY(U,$J,358.3,16473,2)
+104 ;;=^5001844
+105 ;;^UTILITY(U,$J,358.3,16474,0)
+106 ;;=D62.^^61^775^18
+107 ;;^UTILITY(U,$J,358.3,16474,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,16474,1,3,0)
+110 ;;=3^Acute Posthemorrhagic Anemia
+111 ;;^UTILITY(U,$J,358.3,16474,1,4,0)
+112 ;;=4^D62.
+113 ;;^UTILITY(U,$J,358.3,16474,2)
+114 ;;=^267986
+115 ;;^UTILITY(U,$J,358.3,16475,0)
+116 ;;=C92.41^^61^775^19
+117 ;;^UTILITY(U,$J,358.3,16475,1,0)
+118 ;;=^358.31IA^4^2
